The administration of endocrine therapy for 5 years substantially reduces recurrence rates during and after treatment in women with early-stage, estrogen-receptor (ER)-positive breast cancer. Extending such therapy beyond 5 years offers further protection but has additional side effects. Obtaining data on the absolute risk of subsequent distant recurrence if therapy stops at 5 years could help determine whether to extend treatment.
20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years / Pan, H., Gray, R., Braybrooke, J., Davies, C., Taylor, C., Mcgale, P., Peto, R., Pritchard, K.I., Bergh, J., Dowsett, M., Hayes, D.F., De Laurentiis, M.. - In: THE NEW ENGLAND JOURNAL OF MEDICINE. - ISSN 0028-4793. - 377:19(2017), p. 1836-1846. [10.1056/NEJMoa1701830]
20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years
De Laurentiis, MichelinoMembro del Collaboration Group
2017
Abstract
The administration of endocrine therapy for 5 years substantially reduces recurrence rates during and after treatment in women with early-stage, estrogen-receptor (ER)-positive breast cancer. Extending such therapy beyond 5 years offers further protection but has additional side effects. Obtaining data on the absolute risk of subsequent distant recurrence if therapy stops at 5 years could help determine whether to extend treatment.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
